Full Text View
Tabular View
No Study Results Posted
Related Studies
Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
This study has been completed.
Study NCT00077402   Information provided by National Cancer Institute (NCI)

First Received on February 10, 2004.   Last Updated on May 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
fenretinide
Additional drug interventions recognized in this trial
Hormones
More general drug interventions related to this trial
Anticarcinogenic Agents
Antineoplastic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Cancer Therapeutics Research Group
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services